



# INDO-BANGLA PHARMACEUTICALS LIMITED

729, COLLEGE ROAD, BARISAL SADAR, BARISAL-8200, BANGLADESH

PHONE: +88-0967-8777995; FAX: +88-04-312174977

E-mail: info@indo-banglapharma.com;

WEBSITE: www.indo-banglapharma.com

## Second Quarter (Half Yearly) Un-Audited Financial Statement as at December 31, 2018

### STATEMENT OF FINANCIAL POSITION (Un-Audited) As at 31 December 2018

Particulars	Notes	Amounts in Taka	
		31st Dec, 2018	30th June, 2018
<b>ASSETS:</b>			
<b>Non-current Assets:</b>			
Property, Plant and Equipment	3.00	716,286,755	648,473,901
Capital Work In Progress	4.00	-	5,545,920
<b>Current Assets:</b>			
Inventories	5.00	183,954,045	166,752,790
Trade & Other Receivables		215,401,601	186,296,158
Advance, Deposits and Prepayments	6.00	133,999,762	119,219,048
Cash and Cash equivalents	7.00	273,908,719	91,679,619
<b>TOTAL ASSETS</b>		<b>1,523,550,882</b>	<b>1,219,967,436</b>
<b>OWNER'S EQUITY AND LIABILITIES</b>			
<b>Owner's Equity:</b>			
Share Capital		1,023,000,000	730,000,000
Retained Earnings		279,970,672	306,100,643
<b>NON-CURRENT LIABILITIES</b>			
Deferred Tax Liability	8.00	80,102,265	67,249,601
<b>Current Liabilities:</b>			
Provision for WPPF		12,279,276	7,576,461
Trade Payables		11,609,877	6,541,572
Provision for Taxes		111,907,421	97,573,822
Liabilities for Expenses		4,681,371	4,925,336
<b>TOTAL OWNER'S EQUITY AND LIABILITIES</b>		<b>1,523,550,882</b>	<b>1,219,967,436</b>
<b>Net Asset Value (NAV) Per Share</b>	16.00	<b>12.74</b>	<b>14.19</b>

sd/- Chief Financial Officer      sd/- Company Secretary      sd/- Director      sd/- Chairman      sd/- Managing Director  
Dated : Dhaka 30-Jan-19

### Statement Of Changes In Equity (Un-Audited) For the Second quarter ended 31st December 2018

Particulars	Share Capital	Retained Earnings	Total Equity
Balance as at 01-07-2018	730,000,000	306,100,643	1,036,100,643
Issue of share Capital (IPO)	200,000,000	-	200,000,000
Issue of share Capital (Bonus)	93,000,000	(93,000,000)	-
Net Profit for the period	-	66,870,029	66,870,029
Balance as at 31-12-2018	<b>1,023,000,000</b>	<b>279,970,672</b>	<b>1,302,970,672</b>

### Statement Of Changes In Equity For the Second quarter ended 31 December 2017

Particulars	Share Capital	Retained Earnings	Total Equity
Balance as at 01-07-2017	730,000,000	207,606,643	937,606,643
Net Profit for the period	-	48,713,701	48,713,701
Balance as at 31-12-2017	<b>730,000,000</b>	<b>256,320,344</b>	<b>986,320,344</b>

sd/- Chief Financial Officer      sd/- Company Secretary      sd/- Director      sd/- Chairman      sd/- Managing Director  
Dated : Dhaka 30-Jan-19

### Statement Of Cash Flows (Un-Audited) For the Period ended 31st December, 2018

Particulars	Amounts in Taka	
	31st Dec, 2018	31st Dec, 2017
<b>Cash Flow from Operating Activities</b>		
Cash receipts from customers	339,125,850	301,562,495
Cash receipts from others income	4,826,730	3,320,547
Cash payment to Suppliers	(207,564,452)	(209,226,816)
Cash payment to Employees	(36,890,601)	(36,343,262)
Cash payment to Others	(22,295,380)	(32,936,403)
Cash Generate from operation	67,202,147	26,376,562
Cash payment against income Tax	(7,244,683)	(7,941,651)
<b>Net Cash from Operating Activities</b>	<b>59,957,464</b>	<b>18,434,911</b>
<b>Cash Flow from Investing Activities</b>		
Acquisition of property, plant and equipment	(6,060,235)	(724,220)
Paid for Work In Progress	-	(6,791,770)
Paid for land (Gazipur)	(25,000,000)	-
Advance paid for LC Margin Machinery	(768,129)	(36,029,682)
<b>Net Cash used in Investing Activities</b>	<b>(31,828,364)</b>	<b>(43,545,672)</b>
<b>Cash Flow from Financing Activities</b>		
Proceeds from issue of share capital	200,000,000	-
Cash payment to IPO Expenses	(15,900,000)	-
<b>Net Cash from Financing Activities</b>	<b>184,100,000</b>	-
<b>Net increase in Cash and Cash equivalents</b>	<b>182,229,100</b>	<b>(25,110,761)</b>
Cash and Cash Equivalents at beginning of the period	51,679,619	116,812,231
<b>Cash and Cash Equivalent at end of the Period</b>	<b>273,908,719</b>	<b>91,701,470</b>
<b>Net Operating Cash Flows Per Share (NOCFPS)</b>	<b>0.63</b>	<b>0.22</b>

sd/- Chief Financial Officer      sd/- Company Secretary      sd/- Director      sd/- Chairman      sd/- Managing Director  
Dated : Dhaka 30-Jan-19

### STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Un-Audited) For the Second quarter ended 31 December 2018

Particulars	Notes	Amount in Taka			
		01/07/2018 to 31/12/2018	01/07/2017 to 31/12/2017	01/10/2018 to 31/12/2018	01/10/2017 to 31/12/2017
Net Sales Revenue	9.00	355,287,896	320,331,242	189,405,087	161,100,391
Less: Cost of Sales	10.00	212,108,102	191,917,403	113,306,961	96,983,568
<b>Gross Profit</b>		<b>143,179,794</b>	<b>128,413,839</b>	<b>76,098,126</b>	<b>64,116,823</b>
<b>Less: Operating Expenses:</b>					
Administrative Expenses	11.00	13,888,380	16,881,440	6,750,730	10,737,799
Selling & Distributing Expenses	12.00	36,302,435	36,117,474	17,637,466	18,052,275
<b>Profit from Operations</b>		<b>92,988,979</b>	<b>75,414,925</b>	<b>51,709,930</b>	<b>35,326,749</b>
Add: Non Operating Income:		5,770,127	3,276,437	3,819,492	1,300,635
<b>Profit before Contribution to WPPF &amp; Welfare Fund</b>		<b>98,759,106</b>	<b>78,691,362</b>	<b>55,529,422</b>	<b>36,627,384</b>
Less: Contribution to WPPF & Welfare Fund		4,702,815	3,747,208	2,644,258	1,744,161
<b>Profit before Tax</b>		<b>94,056,291</b>	<b>74,944,154</b>	<b>52,885,164</b>	<b>34,883,223</b>
<b>Less: Income Tax Expenses:</b>					
Current Tax		27,186,263	26,230,453	15,204,853	12,209,128
Deferred Tax		14,333,599	13,761,594	8,262,385	6,024,393
		12,852,664	12,468,859	6,942,468	6,184,725
<b>Net Profit for the period</b>		<b>66,870,029</b>	<b>48,713,701</b>	<b>37,680,311</b>	<b>22,674,094</b>
<b>Basic Earnings per share (EPS)</b>	13.00	<b>0.71</b>	<b>0.59</b>	<b>0.37</b>	<b>0.28</b>

sd/- Chief Financial Officer      sd/- Company Secretary      sd/- Director      sd/- Chairman      sd/- Managing Director  
Dated : Dhaka 30-Jan-19

"The details of the Published Second Quarterly Financial Statements are available in the website of the company. The address of the website is www.indo-banglapharma.com"